← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Platinum compounds
satraplatin
L01XA04
Forms & Strengths
- Oral capsules: 25 mg
- Oral capsules: 50 mg
- Oral capsules: 100 mg
Adult Dosing
- Investigational dosage in clinical trials: 80 mg/m² PO once daily on days 1 through 5 of a 21-day cycle
- Dose modifications required based on hematologic and non-hematologic toxicities
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Investigated primarily for hormone-refractory prostate cancer
- Evaluated in various solid tumors including small cell lung cancer and ovarian cancer
Mechanism of Action
- Platinum-based antineoplastic agent
- Binds to DNA to form intra- and inter-strand cross-links, inhibiting DNA replication and transcription, leading to cell apoptosis
Contraindications
- Hypersensitivity to satraplatin or other platinum-containing compounds
- Severe bone marrow suppression or baseline severe myelosuppression
- Severe renal impairment (depending on protocol specifications)
Adverse Reactions
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and vomiting
- Fatigue
- Diarrhea
- Peripheral neuropathy
- Decreased appetite
Drug Interactions
- Avoid concurrent use with nephrotoxic agents to reduce risk of enhanced renal toxicity
- Caution with myelosuppressive drugs due to additive bone marrow suppression
- Substrates or inhibitors of CYP450 enzymes have minimal direct interaction, as satraplatin undergoes non-enzymatic reduction
Curated Content: Needs Vetting Before Put to Clinical Use